Orbital inflammatory pseudotumor: new advances in diagnosis, pathogenesis, and treatment

Ding ZX, Lip G, Chong V. Idiopathic orbital pseudotumour. Clin Radiol. 2011;66(9):886–92. Chaudhry IA, Shamsi FA, Arat YO, et al. Orbital pseudotumor: distinct diagnostic features and management. Middle East Afr J Ophthalmol. 2008;15(1):17–27. Weber AL, Romo LV, Sabates NR. Pseudotumor of the orbit—clinical, pathologic, and radiologic evaluation. Radiol Clin N Am. 1999;37(1):151. Shields JA, Shields CL, Scartozzi R. Survey of 1264 patients with orbital tumors and simulating lesions. Ophthalmology. 2004;111(5):997–1008. Kim UR, Khazaei H, Stewart WB, et al. Spectrum of orbital disease in south India: an aravind study of 6328 consecutive patients. Ophthalmic Plast Reconstr Surg. 2010;26(5):315–22. Goto H, Yamakawa N, Komatsu H, et al. Clinico-epidemiological analysis of 1000 cases of orbital tumors. Jpn J Ophthalmol. 2021;65(5):704–23. Proia AD, McCall CM, Kim JS, et al. Idiopathic orbital inflammation with bone destruction and extension into the paranasal sinuses. Surv Ophthalmol. 2019;64(3):365–79. Orgaz MS, Grabowska A, Bellido EC, et al. Idiopathic sclerosing orbital inflammation with intranasal extension. Orbit. 2010;29(2):106–9. Tedeschi E, Ugga L, Caranci F, et al. Intracranial extension of orbital inflammatory pseudotumor: a case report and literature review. BMC Neurol. 2016;16(1):1–6. Mombaerts I, Bilyk JR, Rose GE, et al. Consensus on diagnostic criteria of idiopathic orbital inflammation using a modified delphi approach. JAMA Ophthalmol. 2017;135(7):769. Mombaerts I, Goldschmeding R, Schlingemann RO, et al. What is orbital pseudotumor? Surv Ophthalmol. 1996;41(1):66–78. Ren MW, Du Y, Ren S, et al. Epstein-Barr virus-encoded small RNAs in idiopathic orbital inflammatory pseudotumor tissues: a comparative case series. Int J Ophthalmol. 2017;10(8):1268–72. Mombaerts I, Rose GE, Garrity JA. Orbital inflammation: biopsy first. Surv Ophthalmol. 2016;61(5):664–9. Chen J, Ye H, Xiao W, et al. Increased dysfunctional and plastic regulatory t cells in idiopathic orbital inflammation. Front Immunol. 2021;12:634847. Zborowska B, Ghabrial R, Selva D, et al. Idiopathic orbital inflammation with extraorbital extension: case series and review. Eye. 2006;20(1):107–13. Atabay C, Tyutyunikov A, Scalise D, et al. Serum antibodies reactive with eye muscle membrane antigens are detected in patients with nonspecific orbital inflammation. Ophthalmology. 1995;102(1):145–53. Wladis EJ, Iglesias BV, Adam AP, et al. Toll-like receptors in idiopathic orbital inflammation. Ophthalmic Plast Reconstr Surg. 2012;28(4):273–6. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373–84. Clanchy FIL, Sacre SM. Modulation of toll-like receptor function has therapeutic potential in autoimmune disease. Expert Opin Biol Ther. 2010;10(12):1703–16. Mori L, Bellini A, Stacey M, et al. Fibrocytes contribute to the myofibroblast population in wounded skin and originate from the bone marrow. Exp Cell Res. 2005;304(1):81–90. Schmidt M, Sun G, Stacey MA, et al. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J Immunol. 2003;171(1):380–9. Gillespie EF, Papageorgiou KI, Fernando R, et al. Increased expression of TSH receptor by fibrocytes in thyroid-associated ophthalmopathy leads to chemokine production. J Clin Endocrinol Metab. 2012;97(5):E740–6. Galligan CL, Siminovitch KA, Keystone EC, et al. Fibrocyte activation in rheumatoid arthritis. Rheumatology. 2009;49(4):640–51. Nihlberg K, Larsen K, Hultgårdh-Nilsson A, et al. Tissue fibrocytes in patients with mild asthma: a possible link to thickness of reticular basement membrane? Respir Res. 2006;7(1):1–9. Noble PW, Homer RJ. Idiopathic pulmonary fibrosis: new insights into pathogenesis. Clin Chest Med. 2004;25(4):749–58. Sakai N, Wada T, Matsushima K, et al. The renin-angiotensin system contributes to renal fibrosis through regulation of fibrocytes. J Hypertens. 2008;26(4):780–90. Lee BJ, Atkins S, Ginter A, et al. Increased CD40+ fibrocytes in patients with idiopathic orbital inflammation. Ophthalmic Plast Reconstr Surg. 2015;31(3):202–6. Hsuan JD, Selva D, McNab AA, et al. Idiopathic sclerosing orbital inflammation. Arch Ophthalmol. 2006;124(9):1244–50. Rosenbaum JT, Choi D, Wilson DJ, et al. Fibrosis, gene expression and orbital inflammatory disease. Br J Ophthalmol. 2015;99(10):1424–9. Wladis EJ, Iglesias BV, Gosselin EJ. Characterization of the molecular biologic milieu of idiopathic orbital inflammation. Ophthalmic Plast Reconstr Surg. 2011;27(4):251–4. Hamza T, Barnett JB, Li B. Interleukin 12 a key immunoregulatory cytokine in infection applications. Int J Mol Sci. 2010;11(3):789–806. Jin R, Ma XM, Zhao PX et al. Gene expression profiling of idiopathic orbital inflammatory pseudotumors. In: The 4th IEEE international conference on bioinformatics and biomedical engineering (ICBBE2010). USA; 2010. p. 1–6. Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775–87. Vent-Schmidt J, Han JM, MacDonald KG, et al. The role of FOXP3 in regulating immune responses. Int Rev Immunol. 2013;33(2):110–28. Gardner A, de Mingo PÁ, Ruffell B. Dendritic cells and their role in immunotherapy. Front Immunol. 2020;11:924. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12(4):265–77. Musumeci A, Lutz K, Winheim E, et al. What makes a pDC: recent advances in understanding plasmacytoid dc development and heterogeneity. Front Immunol. 2019;10:1222. Shaw J, Wang Y-H, Ito T, et al. Plasmacytoid dendritic cells regulate B-cell growth and differentiation via CD70. Blood. 2010;115(15):3051–7. Laban KG, Rijken R, Hiddingh S, et al. cDC2 and plasmacytoid dendritic cells diminish from tissues of patients with non-Hodgkin orbital lymphoma and idiopathic orbital inflammation. Eur J Immunol. 2020;50(4):548–57. Brimnes MK, Svane IM, Johnsen HE. Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma. Clin Exp Immunol. 2006;144(1):76–84. Miles JJ, McCluskey J, Rossjohn J, et al. Understanding the complexity and malleability of T-cell recognition. Immunol Cell Biol. 2015;93(5):433–41. Pai JA, Satpathy AT. High-throughput and single-cell T cell receptor sequencing technologies. Nat Methods. 2021;18(8):881–92. Cao X, Wa Q, Wang Q, et al. High throughput sequencing reveals the diversity of TRB-CDR3 repertoire in patients with psoriasis vulgaris. Int Immunopharmacol. 2016;40:487–91. Sui W, Hou X, Zou G, et al. Composition and variation analysis of the TCR β-chain CDR3 repertoire in systemic lupus erythematosus using high-throughput sequencing. Mol Immunol. 2015;67(2):455–64. Shao L, Liu Y, Mei J, et al. High-throughput sequencing reveals the diversity of TCR β chain CDR3 repertoire in patients with severe acne. Mol Immunol. 2020;120:23–31. Culligan B. Orbital myositis following streptococcal pharyngitis in a pediatric patient. Optometry J Am Optometric Assoc. 2005;76(4):250–8. Mozzo E, Donà D, Zannin ME, et al. Ocular involvement in an HIV-infected patient: not always an infectious disease. An interesting case without apparent cause. Int J STD AIDS. 2016;27(12):1130–3. Benson WH, Linberg JV, Weinstein GW. Orbital pseudotumor in a patient with AIDS. Am J Ophthalmol. 1988;105(6):697–8. Kawasaki A, Borruat F-X. An unusual presentation of herpes zoster ophthalmicus: orbital myositis preceding vesicular eruption. Am J Ophthalmol. 2003;136(3):574–5. Cruz AAV, Alves-Ferreira EVC, Milbratz-Moré G, et al. Sclerosing orbital inflammation caused by Leishmania braziliensis. Am J Trop Med Hyg. 2017;96(1):197–9. Jin R, Zhao PX, Ma XM, et al. Quantification of Epstein-Barr virus DNA in patients with idiopathic orbital inflammatory pseudotumor. PLoS ONE. 2013;8(1):e50812. Leo M, Maggi F, Dottore GR, et al. Graves’ orbitopathy, idiopathic orbital inflammatory pseudotumor and Epstein-Barr virus infection: a serological and molecular study. J Endocrinol Invest. 2016;40(5):499–503. Nagata K, Hayashi K. Epstein-Barr virus reactivation-induced immunoglobulin production: significance on autoimmunity. Microorganisms. 2020;8(12):1875. Laban KG, Kalmann R, Bekker CPJ, et al. A pan-inflammatory microRNA-cluster is associated with orbital non-Hodgkin lymphoma and idiopathic orbital inflammation. Eur J Immunol. 2019;50(1):86–96. Bashant KR, Vassallo A, Herold C, et al. Real-time deformability cytometry reveals sequential contraction and expansion during neutrophil priming. J Leukoc Biol. 2019;105(6):1143–53. Jin R, Ma XM, Zhao PX et al. Gene expression profiling of idiopathic orbital inflammatory pseudotumors. In: 4th international conference on bioinformatics and biomedical engineering (iCBBE); 2010. Chengdu, Peoples R China. Roman-Blas JA, Jimenez SA. NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthr Cartil. 2006;14(9):839–48. De Bosscher K, Vanden Berghe W, Vermeulen L, et al. Glucocorticoids repress NF-kappa B-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc Natl Acad Sci USA. 2000;97(8):3919–24. Kang MS, Yang HK, Kim N, et al. Clinical features of ocular motility in idiopathic orbital myositis. J Clin Med. 2020;9(4):1165. Schoser BGH. Ocular myositis: diagnostic assessment, differential diagnoses, and therapy of a rare muscle disease—five new cases and review. Clin Ophthalmol (Auckland, NZ). 2007;1(1):37–42. Yan J, Wu P. Idiopathic orbital myositis. J Craniofac Surg. 2014;25(3):884–7. Yuen SJA, Rubin PAD. Idiopathic orbital inflammation—distribution, clinical features, and treatment outcome. Arch Ophthalmol. 2003;121(4):491–9. Khochtali S, Zayani M, Ksiaa I, et al. Syndrome d’inflammation orbitaire idiopathique : à propos de 24 cas. J Fr Ophtalmol. 2018;41(4):333–42. Lieb WE. Idiopathische orbitale Entzündungen. Ophthalmologe. 2021;118(8):777–86. Bijlsma WR, Van’t Hullenaar FC, Mourits MP, et al. Evaluation of classification systems for nonspecific idiopathic orbital inflammation. Orbit. 2012;31(4):238–45. Ben Artsi E, McKelvie PA, McNab AA. Histopathologic findings in idiopathic orbital myositis. Ophthalmology. 2021;128(4):609–16. Sepahdari AR, Politi LS, Aakalu VK, et al. Diffusion-weighted imaging of orbital masses: multi-institutional data support a 2-ADC threshold model to categorize lesions as benign, malignant, or indeterminate. Am J Neuroradiol. 2014;35(1):170–5. Laban KG, Kalmann R, Leguit RJ, et al. Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease. EJNMMI Res. 2019;9(1):1–7. Mombaerts I, McNab AA. Idiopathic orbital myositis revisited. Curr Rheumatol Rep. 2022;24(1):20–6. Dagi Glass LR, Freitag SK. Orbital inflammation: corticosteroids first. Surv Ophthalmol. 2016;61(5):670–3. Kubota T. Corticosteroids or biopsy for idiopathic orbital inflammation. Surv Ophthalmol. 2017;62(2):253–5. Luemsamran P, Rootman J, White VA, et al. The role of biopsy in lacrimal gland inflammation: a clinicopathologic study. Orbit. 2017;36(6):411–8. Eng TY, Abugideiri M, Chen TW, et al. Radiation therapy for benign disease. Hematol Oncol Clin North Am. 2020;34(1):229–51. Abad S, Héran F, Terrada C, et al. Orbitopathies inflammatoires Que doit savoir l’interniste ? Rev Med Interne. 2018;39(9):746–54. Espinoza GM. Orbital inflammatory pseudotumors: etiology, differential diagnosis, and management. Curr Rheumatol Rep. 2010;12(6):443–7. Swamy BN, McCluskey P, Nemet A, et al. Idiopathic orbital inflammatory syndrome: clinical features and treatment outcomes. Br J Ophthalmol. 2007;91(12):1667–70. Olsen TG, Heegaard S. Orbital lymphoma. Surv Ophthalmol. 2019;64(1):45–66. Yan J, Wu Z, Li Y. The differentiation of idiopathic inflammatory pseudotumor from lymphoid tumors of orbit: analysis of 319 cases. Orbit. 2004;23(4):245–54. Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362(8):726–38. Mottow LS, Jakobiec FA. Idiopathic inflammatory orbital pseudotumor in childhood. I. Clinical characteristics. Arch Ophthalmol (Chicago, Ill: 1960). 1978;96(8):1410–7. Celebi FZO, Tasdemir-Ertugrul G, Oguz MM, et al. Orbital pseudotumor/idiopathic orbital inflammation syndrome: a rare disease in childhood. Gazi Med J. 2018;29(3):229–30. Yan J, Qiu H, Wu Z, et al. Idiopathic Orbital inflammatory pseudotumor in Chinese children. Orbit. 2009;25(1):1–4. Ishihara R, Jain SF, Perry D, et al. Orbital pseudotumor as the presenting symptom of Crohn’s disease in a male child. Am J Ophthalmol Case Rep. 2020;18: 100669. Nuri O, Mohamad Fekredeen A, Abinash S, et al. Keep an eye out for crohn’s disease: orbital myositis as the initial sign before gastrointestinal manifestations. Eur J Case Rep Intern Med. 2020;7: 001964. Tsukikawa M, Lally SE, Shields CL, et al. Idiopathic orbital pseudotumor preceding systemic inflammatory disease in children. J Pediatr Ophthalmol Strabismus. 2019;56(6):373–7. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–50. Rosenbaum JT, Choi D, Wilson DJ, et al. Molecular diagnosis of orbital inflammatory disease. Exp Mol Pathol. 2015;98(2):225–9. Rosenbaum JT, Choi D, Wilson DJ, et al. Orbital pseudotumor can be a localized form of granulomatosis with polyangiitis as revealed by gene expression profiling. Exp Mol Pathol. 2015;99(2):271–8. Rosenbaum JT, Choi D, Harrington CA, et al. Gene expression profiling reveals heterogeneity of nonspecific inflammation affecting the lacrimal gland. Investig Ophthalmol Vis Sci. 2017;58(8):5618. Young SM, Chan ASY, Al Jajeh I, et al. Clinical features and treatment outcomes of orbital inflammatory disease in singapore: a 10-year clinicopathologic review. Ophthalmic Plast Reconstr Surg. 2017;33(3):182–8. Eshraghi B, Sonbolestan SA, Abtahi M-A, et al. Clinical characteristics, histopathology, and treatment outcomes in adult and pediatric patients with nonspecific orbital inflammation. J Curr Ophthalmol. 2019;31(3):327–34. Mendenhall WM, Lessner AM. Orbital pseudotumor. Am J Clin Oncol. 2010;33(3):304–6. Avni-Zauberman N, Tripathy D, Rosen N, et al. Relapsing migratory idiopathic orbital inflammation: six new cases and review of the literature. Br J Ophthalmol. 2012;96(2):276–80. Reggie S, Neimkin M, Holds J. Intralesional corticosteroid injections as treatment for non-infectious orbital inflammation. Orbit. 2017;37(1):41–7. Leibovitch I, Prabhakaran VC, Davis G, et al. Intraorbital injection of triamcinolone acetonide in patients with idiopathic orbital inflammation. Arch Ophthalmol. 2007;125(12):1647–51. Fionda B, Pagliara MM, Lancellotta V, et al. The role of radiotherapy in orbital pseudotumor: a systematic review of literature. Ocular Immunol Inflamm. 2021;30:1162–7. Isobe K, Uno T, Kawakami H, et al. Radiation therapy for idiopathic orbital myositis: two case reports and literature review. Radiat Med. 2004;22(6):429–31. Gumus K, Mirza GE, Cavanagh HD, et al. Topical cyclosporine a as a steroid-sparing agent in steroid-dependent idiopathic ocular myositis with scleritis: a case report and review of the literature. Eye Contact Lens Sci Clin Pract. 2009;35(5):275–8. Carruth BP, Wladis EJ. Inflammatory modulators and biologic agents in the treatment of idiopathic orbital inflammation. Curr Opin Ophthalmol. 2012;23(5):420–6. Bielory L, Frohman LP. Low-dose cyclosporine therapy of granulomatous optic neuropathy and orbitopathy. Ophthalmology. 1991;98(11):1732–6. Smith JR, Rosenbaum JT. A role for methotrexate in the management of non-infectious orbital inflammatory disease. Br J Ophthalmol. 2001;85(10):1220–4. Galor A, Jabs DA, Leder HA, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology. 2008;115(10):1826–32. Dheer D, Jyoti, Gupta PN, et al. Tacrolimus: an updated review on delivering strategies for multifarious diseases. Eur J Pharm Sci. 2018;114:217–27. Wu B, Tong J, Ran Z. Tacrolimus therapy in steroid-refractory ulcerative colitis: a review. Inflamm Bowel Dis. 2020;26(1):24–32. Albaghdadi AJH, Kan FWK. Therapeutic potentials of low-dose tacrolimus for aberrant endometrial features in polycystic ovary syndrome. Int J Mol Sci. 2021;22(6):2872. Ong SC, Gaston RS. Thirty years of tacrolimus in clinical practice. Transplantation. 2021;105(3):484–95. Kim HJ, Lee S, Koo YJ, et al. Tacrolimus for treating orbital and cranial form of idiopathic inflammatory pseudotumors. J Clin Neurol. 2020;16(4):674. Lim L, Suhler EB, Smith JR. Biologic therapies for inflammatory eye disease. Clin Exp Ophthalmol. 2006;34(4):365–74. Wilson MW, Shergy WJ, Haik BG. Infliximab in the treatment of recalcitrant idiopathic orbital inflammation. Ophthalmic Plast Reconstr Surg. 2004;20(5):381–3. Schafranski MD. Idiopathic orbital inflammatory disease successfully treated with rituximab. Clin Rheumatol. 2008;28(2):225–6. Silpa-archa S, Oray M, Preble JM, et al. Outcome of tocilizumab treatment in refractory ocular inflammatory diseases. Acta Ophthalmol. 2016;94(6):e400–6. Sachdeva A, Kramer N, Rosenstein ED. Orbital inflammatory disease: unusual presentation of enthesitis in an HLA-B27 spondyloarthropathy. Ocul Immunol Inflamm. 2012;20(6):468–70. Pakdel F, Haghighi A, Pirmarzdashti N. Disease modifying drugs in idiopathic sclerosing orbital inflammatory syndrome. Orbit. 2021;41:437–46. Adams AB, Kazim M, Lehman TJA. Treatment of orbital myositis with adalimumab (humira). J Rheumatol. 2005;32(7):1374–5. Zhou Y, Fan R, Botchway BOA, et al. Infliximab can improve traumatic brain injury by suppressing the tumor necrosis factor alpha pathway. Mol Neurobiol. 2021;58(6):2803–11. Mitoma H, Horiuchi T, Tsukamoto H, et al. Molecular mechanisms of action of anti-TNF-α agents—comparison among therapeutic TNF-α antagonists. Cytokine. 2018;101:56–63. Mei WQ, Hu HZ, Liu Y, et al. Infliximab is superior to other biological agents for treatment of active ulcerative colitis: a meta-analysis. World J Gastroenterol. 2015;21(19):6044–51. Heiberg MS, Nordvåg B-Y, Mikkelsen K, et al. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study. Arthritis Rheum. 2005;52(8):2506–12. van der Heijde DSE, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthr Rheum. 2005;52(2):582–91. Bewtra M, Lichtenstein GR. Infliximab use in Crohn’s disease. Expert Opin Biol Ther. 2005;5(4):589–99. Papamichael K, Clarke WT, Vande Casteele N, et al. Comparison of assays for therapeutic monitoring of infliximab and adalimumab in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2021;19(4):839. Hyde C, Bryan S, Juarez-Garcia A, et al. Infliximab for the treatment of ulcerative colitis. Health Technol Assess. 2009;13(Suppl 3):7–12. Kanemaru H, Makino T, Jinnin M, et al. Case of neuro-Behçet’s disease successfully maintained a remission using infliximab for 2 years. J Dermatol. 2013;40(8):632–4. Dai C, Shih S, Ansari A, et al. Biologic therapy in the treatment of cutaneous sarcoidosis: a literature review. Am J Clin Dermatol. 2019;20(3):409–22. Garrity JA, Coleman AW, Matteson EL, et al. Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab. Am J Ophthalmol. 2004;138(6):925–30. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure. Circulation. 2003;107(25):3133–40. van der Klooster JM, Bosman RJ, Oudemans-van Straaten HM, et al. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med. 2003;29(12):2327–9. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001;44(12):2862–9. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent. N Engl J Med. 2001;345(15):1098–104. Kaegi C, Wuest B, Schreiner J, et al. Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders. Front Immunol. 2019;10:1990. Gürcan HM, Keskin DB, Stern JNH, et al. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol. 2009;9(1):10–25. Suhler EB, Lim LL, Beardsley RM, et al. Rituximab therapy for refractory orbital inflammation results of a phase 1/2, dose-ranging, randomized clinical trial. Jama Ophthalmol. 2014;132(5):572–8. Abou-Hanna JJ, Tiu Teo HM, Thangavel R, et al. Long-term follow up of systemic rituximab therapy as first-line and salvage therapy for idiopathic orbital inflammation and review of the literature. Orbit. 2021;41(3):297–304. Yazici B, Cekic S, Yalcinkaya U, et al. Rituximab therapy for recalcitrant idiopathic sclerosing orbital inflammation. Ophthalmic Plast Reconstr Surg. 2020;37(3):e91–7. Abell RG, Patrick A, Rooney KG, et al. Complete resolution of idiopathic sclerosing orbital inflammation after treatment with rituximab. Ocul Immunol Inflamm. 2013;23(2):176–9. Sheppard M, Laskou F, Stapleton PP, et al. Tocilizumab (Actemra). Hum Vaccin Immunother. 2017;13(9):1972–88. Artaechevarria Artieda J, Tapias EI. Tocilizumab in a case of refractory idiopathic orbital inflammation: 6-year follow-up outcomes. Case Rep Ophthalmol. 2020;11(2):299–305. Evans J, Steel L, Borg F, et al. Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis. RMD Open. 2016;2(1): e000137. Antonio AA, Santos RN, Abariga SA. Tocilizumab for giant cell arteritis. Cochrane Database Syst Rev. 2021;8(8): CD013484. Hoy SM. Adalimumab: a review in non-infectious non-anterior uveitis. BioDrugs. 2017;31(2):135–42. Zangrilli A, Bavetta M, Bianchi L. Adalimumab in children and adolescents with severe plaque psoriasis: a safety evaluation. Expert Opin Drug Saf. 2020;19(4):433–8. Hasegawa E, Takeda A, Yawata N, et al. The effectiveness of adalimumab treatment for non-infectious uveitis. Immunol Med. 2019;42(2):79–83. Nuti F, Fiorino G, Danese S. Adalimumab for the treatment of pediatric Crohn’s disease. Expert Rev Clin Immunol. 2015;11(9):963–72. Kapadia MK, Rubin PAD. The emerging use of TNF-alpha inhibitors in orbital inflammatory disease. Int Ophthalmol Clin. 2006;46(2):165–81. Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Saf. 2004;27(5):307–24. Kieseier BC, Mathey EK, Sommer C, et al. Immune-mediated neuropathies. Nat Rev Dis Primers. 2018;4:31. Harris GJ. Idiopathic orbital inflammation: a pathogenetic construct and treatment strategy—the 2005 ASOPRS Foundation lecture. Ophthalmic Plast Reconstr Surg. 2006;22(2):79–86. Rodriguez Torres Y, Azad F, Lin X. Treatment of recalcitrant orbital inflammatory syndrome with plasmapheresis therapy. BMJ Case Rep. 2020;13(1):e232379. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2012;15(1):195–218. Lal B, Kapoor AK, Agrawal PK, et al. Role of curcumin in idiopathic inflammatory orbital pseudotumours. Phytother Res. 2000;14(6):443–7. Chen YM, Hu FR, Liao SL. Idiopathic sclerosing orbital inflammation—a case series study. Ophthalmologica. 2010;224(1):55–8. Neems L, Echalier EL, Subramanian PS. Orbital tumors and inflammatory disorders: diagnosis and management. Int Ophthalmol Clin. 2018;58(2):181–95.